Back to Authors

Ailawadhi, Sikander

https://orcid.org/0000-0002-8377-8111

A5044589378 | I1330342723

Mayo Clinic

Citations 383

Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7237-7238

10.1182/blood-2022-169533

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9904-9905

10.1182/blood-2022-164667

Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9331-9332

10.1182/blood-2022-165377

Real-World Assessment of Second Primary Malignancies in a Treated and Untreated Chronic Lymphocytic Leukemia Population in the United States

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8040-8041

10.1182/blood-2022-158139

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8089-8091

10.1182/blood-2022-158627

Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10165-10166

10.1182/blood-2022-165209

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4349-4351

10.1182/blood-2022-166609

The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7506-7508

10.1182/blood-2022-165266

Advancing CAR T-Cell Care in Relapsed/Refractory Multiple Myeloma: Insights from a Collaborative Quality Improvement Initiative

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 5064-5065

10.1182/blood-2022-166454

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10017-10019

10.1182/blood-2022-167181